GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abiomed Inc (NAS:ABMD) » Definitions » PE Ratio (TTM)

Abiomed (Abiomed) PE Ratio (TTM) : 65.47 (As of Apr. 26, 2024)


View and export this data going back to 1987. Start your Free Trial

What is Abiomed PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-26), Abiomed's share price is $381.02. Abiomed's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $5.82. Therefore, Abiomed's PE Ratio (TTM) for today is 65.47.


The historical rank and industry rank for Abiomed's PE Ratio (TTM) or its related term are showing as below:

ABMD' s PE Ratio (TTM) Range Over the Past 10 Years
Min: 22.49   Med: 87.01   Max: 615.5
Current: 65.47


During the past 13 years, the highest PE Ratio (TTM) of Abiomed was 615.50. The lowest was 22.49. And the median was 87.01.


ABMD's PE Ratio (TTM) is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 27.355 vs ABMD: 65.47

Abiomed's Earnings per Share (Diluted) for the three months ended in Sep. 2022 was $2.32. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $5.82.

As of today (2024-04-26), Abiomed's share price is $381.02. Abiomed's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2022 was $5.82. Therefore, Abiomed's PE Ratio without NRI for today is 65.47.

During the past 13 years, Abiomed's highest PE Ratio without NRI was 615.50. The lowest was 22.49. And the median was 87.01.

Abiomed's EPS without NRI for the three months ended in Sep. 2022 was $2.32. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2022 was $5.82.

During the past 12 months, Abiomed's average EPS without NRI Growth Rate was 79.60% per year. During the past 3 years, the average EPS without NRI Growth Rate was -19.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 20.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 49.30% per year.

During the past 13 years, Abiomed's highest 3-Year average EPS without NRI Growth Rate was 304.60% per year. The lowest was -150.20% per year. And the median was 7.50% per year.

Abiomed's EPS (Basic) for the three months ended in Sep. 2022 was $2.34. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2022 was $5.88.


Abiomed PE Ratio (TTM) Historical Data

The historical data trend for Abiomed's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abiomed PE Ratio (TTM) Chart

Abiomed Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 118.77 50.91 32.77 64.52 111.15

Abiomed Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.47 124.28 111.15 52.22 42.21

Competitive Comparison of Abiomed's PE Ratio (TTM)

For the Medical Devices subindustry, Abiomed's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abiomed's PE Ratio (TTM) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Abiomed's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Abiomed's PE Ratio (TTM) falls into.



Abiomed PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Abiomed's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=381.02/5.820
=65.47

Abiomed's Share Price of today is $381.02.
Abiomed's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.82.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Abiomed  (NAS:ABMD) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Abiomed PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Abiomed's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Abiomed (Abiomed) Business Description

Traded in Other Exchanges
N/A
Address
22 Cherry Hill Drive, Danvers, MA, USA, 01923
Abiomed Inc provides temporary mechanical circulatory support devices that are primarily used by interventional cardiologists and heart surgeons. The firm's products are used for patients in need of hemodynamic support before, during, or after angioplasty and heart surgery procedures. Abiomed receives the majority of revenue from its Impella product portfolio, which includes percutaneous micro heart pumps with integration motors and sensors and percutaneous catheter-based axial flow pumps. Abiomed generates the majority of its revenue in the United States.
Executives
Matthew T. Plano officer: VP, GLOBAL OPERATIONS C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS MA 01923
Martin P Sutter director 2170 BUCKTHORNE PLACE, SUITE 170, THE WOODLAND TX 77380
David M Weber officer: Chief Operating Officer 2341 ROMANO CIRCLE, PLEASANTON CA 94566
Todd A Trapp officer: Vice President, CFO C/O WATTS WATER TECHNOLOGIES, INC., 815 CHESTNUT STREET, NORTH ANDOVER MA 01845
Michael R Minogue director, officer: President & CEO 22 CHERRY HILL DR, C/O ABIOMED INC, DANVERS MA 01923
Paul Thomas director ONE MILLENNIUM WAY, BRANCHBURG NJ 08876
Paula A Johnson director 22 CHERRY HILL DRIVE, DANVERS MA 01923
Myron L Rolle director 1 NASHUA STREET, APARTMENT 1701, BOSTON MA 02114-1625
Dorothy E Puhy director DANA FARBER CANCER INSTITUTE, 44 BINNEY STREET, RM. D1632, BOSTON MA 02115
Andrew J Greenfield officer: VP Healthcare Solutions 14 HILLSIDE DRIVE, GEORGETOWN MA 01833
Marc A Began officer: VP & General Counsel C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS MA 01923
Michael G Howley officer: Vice President 22 CHERRY HILL DRIVE, DANVERS MA 01923
William J Bolt officer: SVP, DA and QA C/O ABIOMED INC, 22 CHERRY HILL DRIVE, DANVERS MA 01923
Rose Eric A Md director 161 FORT WASHINGTON AVENUE, 7TH FLOOR, NEW YORK NY 10032
Henri A Termeer director ONE KENDALL SQUARE, CAMBRIDGE MA 02139